Relevium to Host Webcast to Discuss Previously Announced Blockchain Project
Momentum Public Relations
Press Release: January 18th, 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTC PINK:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce that it will be hosting a webcast in conjunction with Quantomic LLC to discuss Tagspire, the virtual intelligent e-retail platform and artificial intelligence technology stack.
Management and the Board of Relevium have been monitoring public forums and have received multiple questions regarding the January 11, 2018 announcement of a Joint Venture (the “JV”) between the Company and Quantomic LLC. In order to provide clarity and answer these important questions, the Company will be hosting a Webcast, and invites all stakeholders to participate in this exciting information session.
Webcast Details
Relevium – in conjunction with Quantomic LLC – will be hosting a Q&A information webcast on Monday January 22, 2018 at 16:15 ET with Mr. Aurelio Useche, President and CEO of Relevium, and Mr. Karim Hijazi, Founder and CEO of Quantomic LLC.
Investors can email questions for Management to investors@releviumcorp.com prior to 11:59 a.m. ET on Monday January 22, 2018 and they will be addressed on the webcast at the discretion of Management.
During the webcast, the two CEOs will discuss the genesis of Tagspire, the strategic fit between the companies, and explain their shared vision for this exciting platform and technology. In addition, the Company will seek to answer questions that have been raised by shareholders and give guidance on the direction that the Company foresees for the JV, the proposed initial coin/token offering (the “ICO”) and impact for current Relevium shareholders.
Mr. Aurelio Useche, President and CEO of Relevium stated: “We are excited to join forces with Karim Hijazi, founder and CEO of Quantomic LLC and creator of Tagspire.” Mr. Useche continued: “Karim is an accomplished member and leader in the cyber-security community with a track record of previous exits in this space, making this information session a must attend for all our stakeholders.”
Date | Monday, January 22, 2018 | |
Time | 4:15 p.m. ET | |
Conference dial-ins: | ||
Canada | 1 (647) 497 9389 | 1 888 816 4438 |
United States | 1 (951) 384-3421 | 1 866 901 6455 |
Registration URL | https://attendee.gotowebinar.c |
|
Webinar ID | 673-021-811 |
A recording of the webcast will be available upon request. Please email requests to investors@releviumcorp.com for a link to the recording.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
Edward Ierfino
Investor Relations
+1(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in Financial Technology, Life Sciences, Nutraceutical, Relevium Technologies, Technology
Relevium Drives Top Line Growth for Q1
Momentum Public Relations
Press Release: November 6, 2017
MONTREAL, QUEBEC–(Marketwired – Nov. 6, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on creating value through the acquisition and development of e-brands, online businesses and e-retail technologies in the Health and Wellness space, is pleased to announce top line growth for Q1 in anticipation of its interim filings.
What’s New Here?
- Revenues increased by 47{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for the newly acquired BioGanix business in Q1, as compared to sales during the same period last year under the previous ownership.
- Number of units sold increased from 27,084 in 2016 to 42,003.
- Number of subscribers is now 225,000, a 60{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} increase and the number of SKUs is now 26 (32 by year end)
What Does This Mean?
In M&A, the first six months of integration tends to be the most critical period, as such:
- Revenue growth is a good indicator that the integration process is going well
- The increase in customer base and the introduction of new products reflect management’s investment in organic growth and brand equity
Why Should Investors Care?
- Management is executing as promised:
(1) Delivering on the first acquisition and
(2) Optimizing the acquired business - Investors can expect continued focus on brand equity and product line expansion
- Following the successful integration period, management is setting the stage for its next execution challenge
First Quarter Disclosure
The Company’s Fiscal Year 2018 started on July 1, 2017 and as such, shareholders can expect to see the full impact of the results from the Bioganix acquisition in Q1 of this new fiscal year, due at the end of this month.
The Company is expecting to hold a conference call for shareholders to discuss the results of Q1, as well as other business developments. The date and time of the conference call is to be announced on a separate press release.
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Edward Ierfino
Investor Relations
Tel: (514) 562-1374
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies
Relevium Files and Provides Comments on the Audited Consolidated Financial Statements
Momentum Public Relations
Press Release: October 31, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 31, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on creating value through the acquisition and development of e-brands, online businesses and e-retail technologies in the Health and Wellness space, is pleased to announce the filing of the company’s Audited Financial Statements and MD&A for the fiscal year ended June 30, 2017 and 2016 on Sedar
News Release Highlights
- An active year focused on acquisitions and its impact on the income statement
- Impact of Bioganix and first quarter of the fiscal year ending June 30, 2018
- Major events impacting our Consolidated Statements of Financial Position
An active fiscal year focused on acquisitions
The fiscal year ended June 30, 2017 was a year dedicated to the identification, evaluation and negotiation with several acquisition targets. As the Audited Consolidated Financial Statements and MD&A reveal, the company’s expenses increased substantially for the fiscal year ended June 30, 2017, primarily the result of the non-cash impairment of the carrying value of the intellectual assets acquired as part of the company’s qualifying transaction in 2015, totaling $747,322. The additional increase in expenses of $567,677 in consulting fees were related primarily to acquisitions and related expenses. The combination of these major categories of expenses resulted in a net and comprehensive loss of $2,584,738 as compared to $1,557,719 in 2016.
Commenting on the results for the reporting period, Aurelio Useche, President and CEO stated: “It was a year dedicated to the execution of our first acquisition in our roll-up strategy. The process was challenging but effective”. Mr Useche added: “The impact from operations of newly acquired Bioganix will only take effect in the company’s Consolidated Financial Statements for the three-month period ended September 30, 2017 (Q1), which will be reported at the end of this month of November”
Major events impacting our Consolidated Statements of Financial Position
The Company reported significant changes to the Consolidated Statements of Financial Position, including an increase in total assets of $6,111,470 from $1,003,682 in 2016 to $7,115,152 in 2017. In parallel, the Company also reported significant changes in total liabilities of $4,343,533, from $447,031 in 2016 to $4,790,564 in 2017. Most of these changes transpired during the last quarter of the fiscal year ended June 30, 2017 and were primarily the result of an equity financing, a debenture financing and the execution of the definitive agreement and deposit to acquire BioGanix.
Commenting on these major events, Aurelio Useche, President and CEO stated: “From the execution of the binding agreement to the close of all three major events six months later, the company’s overall financial position has improved materially, positioning Relevium to continue to execute on the roll-up strategy”. Mr Useche added: “Relevium remains an entrepreneurial venture at heart and every single person in the team, from directors to the actual operators of the business, is guided by this principle in mind: We are Intense, Nimble and Lean”
The company looks forward to continuing to update shareholders.
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Edward Ierfino
Manager, Investor Relations
Tel: (514) 562-1374
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies
Relevium Provides Operational Progress Update and Appoints Senior Marketing Officer
Momentum Public Relations
Press Release: October 27, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 27, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on creating value through the acquisition and development of e-brands, online businesses and e-retail technologies in the Health and Wellness space, is pleased to announce a brief operational update on progress and the appointment of a Senior Marketing Officer.
News Release Highlights
- RLV appoints Senior Marketing Officer
- BioGanix and General Progress Update
- Financial reporting
Appointment of Senior Marketing Officer
Relevium Technologies is pleased to announce it has appointed Abis Hussain as the company’s Senior Marketing Officer, overseeing the company’s overall marketing and branding activities for its current and future portfolio of e-brands.
Mr. Hussain has been actively engaged in the e-marketing space since 2007 and most recently was Director of Influencer Marketing, as well as, Director of Online Marketing at RhythmOne, a global leader in providing streamlined, transparent connections between advertisers and audiences through a combination of differentiated supply, innovative technology and data-driven insights.
While at RhythmOne, Mr. Hussain expanded client communities and focused in locating target audiences by building social media strategies in the United States and Europe. Mr. Hussain was instrumental in increasing brand awareness by 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for various brands and companies including Subaru, Nestle and Kellogg’s and has worked with pro-athletes and influencers on behalf of clients.
Aurelio Useche, CEO of Relevium Technologies stated: ” Abis has a wealth of knowledge in the business of driving internet traffic from sources outside the Amazon ecosystem. Mr. Useche stated further: “The skillset that Abis brings to the table is extremely complimentary to the existing expertise of the operations team which is very Amazon-centric as it stands. Abis has already demonstrated himself as a strong leader and has kicked off great initiatives that will positively impact the performance of our business.”
Business Update
The acquisition of BioGanix has been a successful endeavor for Relevium and for its shareholders. Revenues have continued to grow by an average of 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} versus the same period in 2016 and our customer base continues to expand.
Since July, the Company has been focused on the optimization of the BioGanix brand through internal efforts and through new products and brand extensions. The BioGanix brand continues to expand with the soft launch of four new SKUs in November. The customer and revenues base are expected to continue to grow organically and as planned.
Shareholders can look forward to detailed information about the results from BioGanix for the three-month period ended September 30, 2017 on its first quarter filings due at the end of November 2017.
Shareholders should also be mindful that the financial impact of the operations of the BioGanix brand will not be part of the Audited Financials for the fiscal year ended June 30, 2017, which are due at the end of this month.
The Company’s CEO expects to hold a call for shareholders at the end of November in order to discuss first quarter performance and provide shareholders with an overview of progress and future strategy. Details will be provided in a subsequent press release.
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Edward Ierfino
Manager, Investor Relations
Tel: (514) 562-1374
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Signs LOI to Acquire Nutraceutical Brand
Momentum Public Relations
Press Release: October 25, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 25, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on the acquisition and building of e-retail brands, products and technologies in the health and wellness market, is pleased to announce that it has signed a non-binding Letter Of Intent (the “LOI”) to acquire an American based nutraceutical brand that sells products direct to consumers primarily through the Amazon.com channel in the Vitamins and Dietary Supplements category. The transaction value is currently estimated at US$1.35 million, which shall be subject to adjustment based upon a multiple of earnings before income taxes.
Highlights
- Non-binding LOI for a Nutraceutical brand
- Targeted to close by November 30, 2017
- RLV Executes on guidance issued August 2, 2017
Subject to the positive outcome of a short due diligence period, the negotiation and execution of a mutually satisfactory definitive acquisition agreement and TSX Venture Exchange approval, management estimates that the transaction should close around November 30, 2017. Pursuant to regulatory guidelines, further financial details and related fees regarding the acquisition will be disclosed at the closing of the transaction. The Company does not anticipate the need for outside capital in order to close the transaction as the consideration is expected to consist solely by the issuance of additional equity of the Company which shall be subject to a vesting schedule and associated targets. The Company does not anticipate that a new control person will be created as a result of the proposed transaction.
Once closed, it is intended that the acquired assets will be transferred to Relevium and the operations will be integrated into the current operations being managed by the Company.
Aurelio Useche, President and CEO of Relevium Technologies stated: “We have been diligently looking at accretive assets to add to our portfolio since the acquisition of BioGanix and we are very pleased to execute another line item from our 2017 guidance laid out on August 2, 2017.”
Mr. Useche continued: “Once closed, this transaction will further demonstrate Management’s ability to execute on the M&A strategy and should contribute to top line revenue and EBITDA for Fiscal 2018. Operationally speaking we are ready to continue acquiring, integrating and optimizing brands. The current M&A pipeline remains very healthy and in line with previously stated numbers. We look forward to concluding more transactions on an aggressive schedule.”
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Edward Ierfino
Manager, Investor Relations
(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies
Relevium Changes Auditors and Corporate Update
Momentum Public Relations
Press Release: October 20, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 20, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV) and (FRANKFURT:6BX) (the “Company” or “Relevium”) announced today that it has changed auditors and appointed Ernst & Young LLP, Chartered Professional Accountants, as the Company’s new auditor (the “Successor Auditor“), replacing Nexia Freedman LLP, Chartered Professional Accountants (the “Former Auditor“). At the request of the Company, the Former Auditor has resigned and the Successor Auditor has been appointed as of the effective date of October 11, 2017.
The Company’s Audit Committee and Board of Directors have approved the resignation of the Former Auditor and the appointment of the Successor Auditor. In accordance with National Instrument 51-102 – Continuous Disclosure Obligations, the notice of change of auditor, together with the letter from the Former Auditor and the letter from Successor Auditor have been reviewed by the Company’s Audit Committee and Board of Directors and are available under the Company’s profile at www.sedar.com. There were no reservations or modified opinions in the Former Auditor’s reports in connection with the financial statements of the Company for the Company’s most recent fiscal year and any subsequent period, and there are no “reportable events”, as defined in the National Instrument 51‐102 ‐ Continuous Disclosure Obligations, between the Company and the Former Auditor.
Aurelio Useche, CEO of Relevium Technologies stated “On behalf of our board of directors and the management team, we thank the team at Nexia Freedman for the services provided to the Company. We look forward to working with Ernst & Young, as the Company grows and executes its business plan.”
The Company also announces that, effective August 18, 2017, David A. Johnson has been appointed Corporate Secretary of the Company. Mr. Johnson is an attorney and a trademark agent and has served as an executive officer, director and audit committee member of various public companies listed on the TSX Venture Exchange and the Canadian Stock Exchange. In consideration for Mr. Johnson’s ongoing services as Corporate Secretary and in order to preserve its cash on hand, the Company has agreed, subject to TSX Venture Exchange approval, to issue common shares of the Company to Mr. Johnson at an amount of $2,500 per month whereby the price calculates the volume weighted average price, or VWAP, for the last five (5) trading days of the month.
Aurelio Useche, CEO of Relevium Technologies stated “We welcome the addition of Mr. Johnson to our team. His years of professional experience in public companies, corporate governance and legal knowledge will be a strategic asset to the Company.”
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward-looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Edward Ierfino
Manager, Investor Relations
(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Technologies Reports Revenue of CAD$700,000 in the First 50 Days of Business
Momentum Public Relations
Press Release: October 16, 2017
October 16, 2017 / TheNewswire / MONTREAL, QUEBEC, Momentum PR client, Relevium Technologies., is listed on the TSX Venture Exchange under the symbol: RLV and in Germany on the FSE under the symbol: 6BX.
Momentum PR is pleased to have produced an informative and comprehensive report on Relevium Technologies, available on the Momentum PR website.
Relevium Business Model:
– Montreal-based Relevium Technologies has embarked on an aggressive acquisition plan to become a Canadian brand name in the booming e-commerce health and wellness sector; concentrating on the nutraceutical and cosmeceutical markets.
–Goldstein Research predicts US$300 Billion Nutraceutical Market By 2024
Creating new Brands
-Building new brands for fitness and pet nutraceuticals
BioGanix:
–Relevium has recently closed its acquisition of BioGanix, a profitable health and wellness supplements brand with a product line of 25 best-selling supplements.
-During the first 50 days BioGanix sales reached $CAD 700,000. BioGanix is operating under Relevium’s US subsidiary BGX E-Health.
AgileDSS:
–Relevium hired agileDSS as a data architect to start work on the company’s big data and AI Product Trend-Recognition Engine.
-The company believes that if it is successful, the Product Trend-Recognition Engine would allow it to launch the right products in the right market, long before any competitor.
HempCo:
-In May, Relevium signed an exclusive e-retail agreement with HempCo Food and Fiber, (TSXV:HEMP).
-HempCo sells hemp protein powder, hemp oil and hulled hemp seed nut, under its brand PlanetHemp on a B2B (business-to-business) basis.
-The agreement calls for the joint development of a complete line of hemp-based nutraceutical and nutritional products, for distribution through global e-commerce platforms including Amazon and Jet.com. Relevium will also develop B2C (business-to-consumer).
Research house MarketsandMarkets has predicted that the global wellness supplement market will hit US$249.4 Billion during 2020, up from US$183.1 Billion in 2015.
Relevium Technologies CEO Aurelio Useche describes the sectors like this: “Both nutraceuticals and cosmeceuticals come from the combination of nature and science. They are a combination of natural ingredients with some science behind them.”
The market is being driven by a variety of factors, ranging from increased knowledge about the benefits supplements can provide, to aging boomers wanting to live better longer. Another driver is the increasing belief that natural ingredients are better than synthetic compounds, with far fewer side effects.
Relevium is also in advanced discussions with other e-commerce companies and is targeting the execution of a second acquisition of either a nutraceutical or cosmeceutical company by the end of the year.
“I see the company becoming a portfolio of health and wellness brands that have become well-recognized in the marketplace. In terms of size, we aim for a company with C$500 Million in annual revenues and the ability to offer our investors dividends,” said CEO Aurelio Useche.
Relevium trades on the TSXV as RLV and on the FSE as 6BX. As of October 11, 2017 it closed at C$0.12 and has a 52-week high of C$0.22 and a low of C$0.045. The company has 66,971,466 shares outstanding and a market cap of C$7.9 million.
The Momentum PR informative and comprehensive report on Relevium Technologies is available on the Momentum PR website.
If you would like more information on Relevium; listed on the TSX Venture Exchange under the symbol RLV or would like to arrange an interview with management please contact:
Momentum PR
Juliette Benard, Director Media Relations
+1.450.332.6939
media@momentumpr.com
info@momentumpr.com
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid-cap Canadian listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies through online and offline channels.
Read it on The Newswire
- Published in News Home, Nutraceutical, Relevium Technologies, Technology
Which States are Most Likely to Legalize Cannabis in 2016?
Which States are Most Likely to Legalize Cannabis in 2016?
Lisa Rough – Leafy
https://www.leafly.com/news/politics/what-states-are-most-likely-to-legalize-in-2016
Our 2016 Predictions for Legalization of Cannabis in the U.S.
Cannabis supporters are looking towards November of 2016 with great anticipation. With the presidential election looming, there is guaranteed to be a massive voter turnout and the initiatives that are poised to include legalization of cannabis on the 2016 ballot stand a chance to make some big changes. But which states are most likely to legalize next? Here is what we think for 2016.
Cannabis Legalization is Almost a Sure Thing
NEVADA
If you’re searching for a sure bet, look no further than Nevada. It may have taken this state a while to legalize medical marijuana, but now that it’s on that path to legalization of recreational cannabis, it’s not stopping ‘til the end.Nevada’s was the first state campaign to officially gather the required number of signatures to qualify for the 2016 ballot, submitting 170,000 signatures last December. That’s about 60,000 more signatures than the 101,667 signatures needed, and nearly two years early. Nevada’s already opened a successfulmedical marijuana program that allows reciprocity without any issues. With any luck, it’s locked in on recreational and won’t stop until next November.
CALIFORNIA
One would think that California has a better chance than Nevada at legalization, considering that the state was one of the first to legalize medical marijuana back in 1996. The problem with California was the complete and total lack of statewide regulations to help keep its medical marijuana system in check. Without regulations, Cali’s cannabis scene exploded like the Wild West, causing friction within the city and county jurisdictions that tried to reign it in.
Luckily, Governor Jerry Brown signed three pieces of legislation this year as part of a broad initiative to quickly regulate the medical market before the big push for legalization. Although there are as many as 16 potential recreational measures, the one that seems to be the front runner is known as the Adult Use of Marijuana Act, which is endorsed by Lieutenant Governor Gavin Newsom and several major cannabis advocacy groups.
ARIZONA
Arizona may seem like a logical next state in line to legalize, but it’s got a long road ahead in the fight for legalization. When Arizona voted to legalize medical marijuana in 2010, the initiative won by a measly 4,000 votes, which does not bode well for the state’s recreational legalization initiative, the Campaign to Regulate Marijuana Like Alcohol in Arizona. Furthermore, the campaign has already faced some controversy over advertising efforts.
The latest polling from Arizona State University showed that 49 percent of the state supports legalization, while 51 percent oppose. A previous poll from June indicated that 53 percent support legalization, which shows just how wide the margin of error can be and just how close the 2016 race will likely end up. Looks like Arizona will get down to the wire — every vote will count!
MAINE
Maine has one of the best, most stable medical marijuana programs in the country. It offers a limited number of medical marijuana dispensaries (that cater to out-of-state patients, too!), but Maine’s caregiver program is so robust that dispensaries are less of a necessity and more of an obligation to meet patients’ needs.
Not only that, but on a lower jurisdiction level, cities in Maine have already taken it upon themselves to attempt to legalize on a smaller scale. Portland, South Portland, and Lewiston all attempted to legalize the possession and use of cannabis by adults, and although Portland’s initiative passed with flying colors, the idea was not popular with local authorities. Seems like a sure thing, right?
The state’s legalization initiative, the Marijuana Legalization Act, which would allow anyone over the age of 21 to legally possess up to 2 ½ ounces and grow up to 12 plants for personal use, nearly took a massive blow when the Secretary of State only accepted 51,543 of the 99,299 signatures submitted in support of the initiative, due to a discrepancy in one particular notary’s signature. However, a legal challenge from the organizers forced the Secretary of State to reconsider and accept 11,305 of the 21,797 rejected signatures. This brought the total submitted signatures to 62,848, just over the 61,123 signatures needed to qualify for the November ballot.
Legalization in Maine? Stay tuned!
Fingers Crossed for Cannabis Legalization
CONNECTICUT
Connecticut took the plunge for medical marijuana in 2012, and a year after its first dispensaries opened, its program was running smoothly with a patient base of 6,700 registrants and six state-licensed dispensaries. Not only that, but a poll from the University of New Haven found residents overwhelming support cannabis, with 56 percent polled saying they agreed that legalizing marijuana would have a positive impact on Connecticut’s economy. There were two legalization initiatives considered during the 2015 legislative session that stalled eventually, and Connecticut cops are already preparing for legalization as an inevitability, so the real question is will 2016 be the year it happens?
MICHIGAN
Michigan legalized medical marijuana in 2008, but its relationship with cannabis is strained at best. State legislators go back and forth nearly every session restricting and loosening cannabis laws, even going so far as to outlaw medical dispensaries, essentially forcing business owners to continue operating at risk of prosecution. Additionally, patients in Michigan have dubious legal protection, facing criminal charges for edibles or hash oils due to an oversight in the language of the law.
However, one might argue that Michigan’s muddy cannabis climate has created an environment that is ripe for change. There have been efforts to revise the state’s medical marijuana law, including a bill under consideration right now that would re-legalize medical dispensaries. Several groups have also been trying to make change happen. The Michigan Cannabis Coalitioncreated a legalization initiative but it has not gained traction in several months, while the group MI Legalize is currently on track to collect 252,000 signatures before the June deadline in order to qualify for the 2016 ballot. You can find a location to sign MILegalize’s petition here. May the strongest initiative win!
RHODE ISLAND
Rhode Island is an example of a successful medical marijuana program withreciprocity for out-of-state certified patients, but does it have what it takes to legalize? A poll by Marijuana Policy Project from April 2015 shows some promising numbers, with 57 percent of respondents saying that they would support legalizing marijuana to be regulated like alcohol. Not only that, but Rhode Island also took the prize of highest consumption rate for cannabis two years running, no small feat for the unassuming, 1200-square-mile state.Regulate Rhode Island, the state’s legalization leader, pushed unsuccessfully for 2015 legislation and is ready for its fight to carry over into the next year.
Probably Not Legalizing Cannabis in 2016
DELAWARE
Delaware is certainly a curious case for cannabis. Although the state is slightly larger than Rhode Island, when drafting its medical marijuana program, the state health department restricted the number of dispensaries and now, four years after medical marijuana became legal, there is only one dispensary operating to serve the entire state. Admittedly, there are only 700 patients registered, with requests for other dispensaries to open in other counties, and the program has had nothing but positive feedback, particularly regarding the lack of tax and low-income discounts available.
Earlier this year, Delaware Governor Jack Markell went a step further in decriminalizing the possession of cannabis for personal use. As a result, although there has been a lot of talk about possible legalization in the state, the cannabis decriminalization was enough to appease the masses for now.
MARYLAND
Ah, Maryland, home of “The Wire,” delicious blue crabs, and, coming soon to a county near you, medical marijuana dispensaries. Maryland Governor and Democratic candidate Martin O’Malley played the good guy bydecriminalizing the possession of small amounts of cannabis, and he’s been an instrumental part of implementing the state’s emerging medical marijuana market, which is slated to be quite extensive. All told, there will be nearly 100 dispensary licenses issued, along with 15 cultivator licenses, upping the ante for Maryland to become a major contender jumping into the MMJ realm.
The question now is whether or not Maryland is ready to contend with recreational cannabis yet. Earlier this year, state lawmakers introduced the Marijuana Control and Revenue Act of 2015, a pair of companion bills in the House and Senate, but there hasn’t been any action on them since October. A March 2015 poll puts support for legalization at 52 percent, but it would probably be wise to work out the kinks of a functioning medical program before opening up a new can of worms with recreational legalization.
MASSACHUSETTS
Oh, Massachusetts, we had such high hopes for you. Along with 13,000 medical marijuana patients, we watched the Massachusetts Department of Health bungle the licensing process, the lawsuits that followed, and the realization that your own criteria for selecting distributors was literally impossible for organizations to meet.
Well, the Bay State might be down, but it’s not out. There’s solid support for legalization, showing 53 percent of respondents from early 2014 saying they favor legalizing cannabis. With two competing legalization measures, The Campaign to Regulate Marijuana Like Alcohol in Massachusetts submitted more than the required 64,750 voter signatures, while a countermeasure from Bay State Repeal was still scrambling to garner support.
NEW YORK
The Empire State has been under the microscope since passing legislation to legalize the production of medical cannabis, and everyone’s been waiting and watching as the program has slowly developed. New York has chosen the five producers to cultivate medical marijuana and sales are scheduled to begin in January, but the success or failings of an emerging medical marijuana market could be a defining predictor as to whether the state will be able to follow through with an additional push for recreational cannabis.
With that being said, Senator Liz Krueger (D-NY), cosponsor and author of the Marijuana Regulation and Taxation Act, will continue to push for an end to prohibition in New York. Does it have a chance? Yes, but a slim one.
MISSOURI
Missouri is the last on our list for a reason. While most of these states have a fighting chance due to support, emerging medical marijuana programs, or cannabis-friendly politicians, the sad truth is that Missouri is sorely lacking in all of those things. Okay, that’s not entirely true. Missouri was able to pass a cannabis extract law for epilepsy and seizure patients whose symptoms are resistant to conventional treatment. The Missouri Department of Agriculture even issued licenses for two non-profit organizations, BeLeaf and Noah’s Arc, to produce low-THC cannabis oil. It’s not quite a patient-accessible statewide system of medical dispensaries, but it’s definitely a big step for the Midwestern state.
With that in mind, it’s fairly implausible that Missouri will be able to successfully transition from a severely limited CBD program to full recreational legalization. Maybe someday, but for now, the Show-Me State can show us stronger support than just 36 percent in favor of legalization. Do I sense, perhaps, an expanded medical marijuana program in Missouri’s future?
VERMONT
Vermont’s legalization seemed all but a sure thing. Governor Peter Schumlin had been watching Colorado very closely, even going so far as to organize meetings on the logistics of legalizing cannabis for recreational purposes from a regulatory perspective.
With a February 2015 poll registering 54 percent of Vermonters in support of legalization, the possibility of legalization being pushed through the Vermont legislature seemed imminent, but, alas, when it comes to cannabis, never count your chickens before they’ve hatched.
Support from the current and former Attorney General, and Governor Shumlin’s promise to sign the bill shows that even with the backing of the highest officials in the state, a legislative measure can still fail. S.241 passed through the Senate, but died during a vote from the House. Legalization will have to wait for the Green Mountain State.
View Original: https://www.leafly.com/news/politics/what-states-are-most-likely-to-legalize-in-2016
- Published in Blog, Nutraceutical
Relevium (RLV:tsxv) Announces Partnership Agreement With Hong Kong Based Technology Product Developer
Relevium Announces Partnership Agreement With Hong Kong Based Technology Product Developer
– Momentum Public Relations –
Press Release: July 13, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV) (FRANKFURT:6BX) (the “Company” or “Relevium”) is pleased to announce it has executed a cooperation agreement with Radcon Consulting, a leading “Connected” and “Wearable” technology product designer based in Hong Kong and with offices in China.
Pursuant to the terms of the cooperation agreement, Radcon Consulting will provide Technical Evaluation, Design, Engineering, Project Management and Go-to-Market services in addition to providing investment opportunities in leading edge wearable and connected devices and/or technologies in the areas of Health, Wellness and Sports Performance.
Leena Lakdawala, CEO of Relevium stated: “According to the Consumer Electronics Association®, the connected Personal Health and Wellness market is expected to reach 8 billion by 2018 and Relevium is planning to access this market through unique and innovative products and/or technologies at the peak of the innovation cycle”. She added further “The partnership with Radcon Consulting ensures continued technology flow that will drive the innovation engine behind our consolidation of e-retail asset strategy”
Conrad Lee, CEO of Radcon Consulting stated: “We are excited and delighted to be a partner of Relevium. This cooperation truly strengthens and expands the reach and services for both companies to many innovative and disruptive technologies and investment opportunities”
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
About Radcon Consulting.
Radcon Consulting is a privately held company focused on providing a full suite of services equipped to take concepts from basic design to reality, handling all the technical details while its customers focus on innovation. The company provides Project Management, Electronic/mechanical Design, Software & Firmware Design, Engineering & Manufacturing, Intellectual Property Management, and Go-to-Market as well as other comprehensive services.
- Published in Bio technology, News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Announces Private Placement by Maestro Capital
Relevium Announces Private Placement by Maestro Capital
– Momentum Public Relations –
Press Release: July 6, 2016
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) in conjunction with Maestro Capital Inc. (TSX.P – “MCP”) is pleased to announce that the two parties have agreed to the terms of participation by Maestro in a non-brokered private placement offering (the “Private Placement”).
Pursuant to the agreed terms, Maestro will subscribe by way of subscription agreement for a minimum of 1,500,000 units (the “Units”) of Relevium at a per Unit price of $0.10 for gross proceeds of $150,000. Each unit will consist of one common share in the capital of Relevium (a “Relevium Share”) and one common share purchase warrant, each whole warrant (a “Warrant”) will entitle Maestro to purchase one common share in the capital of Relevium at a per share price of $0.15 for a period of 36 months from the date of closing of the Private Placement.
Completion of the proposed Transaction is subject to a number of conditions, including but not limited to, execution by the parties of a form of subscription agreement for the Private Placement, the receipt of all requisite corporate and regulatory approvals, shareholder and TSX approval. The Exchange’s acceptance of the Transaction will be conditional, among other things, on Maestro filing with the Exchange all documents in compliance with Exchange CPC Policy requirements. The proposed Transaction cannot close until the required approvals are obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Relevium also announced its intention to extend the private placement for a minimum of 5,000,000 Units and a maximum of 10,000,000 under the same terms, which may close in one or more tranches, for total gross proceeds of between $500,000 and $1,000,000. All securities issued by Relevium in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance of the securities in accordance with applicable securities legislation.
Leena Lakdawala, CEO of Relevium stated: “Management is very pleased with the vote of confidence received today from Maestro Capital and its constituents. We have every intention to follow through on our current initiatives and we look forward to welcoming all of Maestro’s shareholders into Relevium”
Relevium also announced its intention to extend the expiry date of the 10,015,466 share purchase warrants issued pursuant to the August 2015 private placement closed concurrently with the completion of its Qualifying Transaction as Ovid Capital. The expiry term of the share purchase warrants will be extended for an additional term of two years and will now expiry on August 18, 2018. The extension of the warrants is subject to the regulatory approval by the TSX.
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
“Leena Lakdawala“
CEO and Director
Learn more by clicking here: www.releviumtechnologies.com
- Published in Bio technology, Life Sciences, News Home, Nutraceutical, Relevium Technologies, Technology
- 1
- 2